logo-loader
Brewin Dolphin

Brewin Dolphin names finance boss of Legal & General Investment Management as its finance director

Back at the end of April, the FTSE 250-listed firm announced the surprise departure of its finance director Andrew Westenberger, who left by mutual agreement on May 16

Handshake
Brewin Dolphin said it is anticipated that Siobhan Boylan will join its board, subject to regulatory approvals, in early 2019

Brewin Dolphin Holdings PLC (LON:BRW) has appointed Siobhan Boylan, currently chief financial officer of Legal & General PLC’s (LON:LGEN) Investment Management unit (LGIM), as its finance director.

The FTSE 250-listed investment group said it is anticipated that Boylan will join its board, subject to regulatory approvals, in early 2019.

READ: Brewin Dolphin announces surprise departure of finance director Andrew Westenberger from May 16

Back at the end of April, Brewin Dolphin announced the surprise departure of its finance director Andrew Westenberger, who left by mutual agreement on May 16.

The company said then that it had already started a search for a permanent replacement for Westenberger, who had been finance director at the group for five years.

In a regulatory announcement on Monday, the firm noted that Boylan has been the finance boss for LGIM, one of Europe's leading asset managers, for the last five years.

Prior to that, it added, she worked at Aviva PLC (LON:AV.) for 12 years where she held several senior roles, including CFO of Aviva North America, and CFO of Aviva Investors from 2007 to 2011.

David Nicol, Brewin Dolphin’s chief executive said: "We are delighted that we have hired someone of Siobhan's outstanding calibre. She has a tremendous track record at several high-profile institutions.

 “She will bring her in-depth knowledge of the financial services industry, as well as management and technical skills, to Brewin Dolphin at a critical stage in our growth trajectory."

Quick facts: Brewin Dolphin

Price: £3.00

Market: LSE
Market Cap: £908.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

15 hours, 14 minutes ago

RNS

Change of External Auditor

2 weeks, 1 day ago

Total Voting Rights

2 weeks, 5 days ago

Change of SID

3 weeks, 4 days ago

Quarterly Trading Update

3 weeks, 5 days ago

2 min read